|
DE69737413T2
(de)
|
1996-01-04 |
2007-10-31 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Bakterioferritin aus helicobacter pylori
|
|
CA2425303A1
(en)
|
2000-10-27 |
2002-05-02 |
John Telford |
Nucleic acids and proteins from streptococcus groups a & b
|
|
JP2004535765A
(ja)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
前立腺癌においてアップレギュレートされた内因性レトロウイルス
|
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
|
ATE545651T1
(de)
|
2002-06-13 |
2012-03-15 |
Novartis Vaccines & Diagnostic |
Vektoren zur expression von hml-2-polypeptiden
|
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
|
DK1549338T3
(da)
|
2002-10-11 |
2011-03-28 |
Novartis Vaccines & Diagnostic |
Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
|
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
JP2006520746A
(ja)
|
2002-12-27 |
2006-09-14 |
カイロン コーポレイション |
リン脂質を含む免疫原性組成物
|
|
WO2004067030A2
(en)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
WO2004092360A2
(en)
|
2003-04-10 |
2004-10-28 |
Chiron Corporation |
The severe acute respiratory syndrome coronavirus
|
|
CA2528007C
(en)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
|
BRPI0415025A
(pt)
|
2003-10-02 |
2006-12-12 |
Chiron Srl |
vacinas lìquidas para sorogrupos meningocócicos múltiplos
|
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
|
EP1722815A1
(en)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza virus vaccines
|
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
|
PT1740217E
(pt)
|
2004-04-30 |
2011-08-02 |
Novartis Ag |
Vacinação meningocócica conjugada
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
|
US9034345B2
(en)
|
2005-01-27 |
2015-05-19 |
Children's Hospital & Research Center Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
|
EP1858919B1
(en)
|
2005-02-18 |
2012-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogens from uropathogenic escherichia coli
|
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
WO2007015441A1
(ja)
|
2005-08-01 |
2007-02-08 |
Hisamitsu Pharmaceutical Co., Inc. |
経皮または経粘膜投与のためのアジュバントおよび製剤
|
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
AU2006310338A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Adminstration routes for priming/boosting with influenza vaccines
|
|
EP3714900A1
(en)
|
2005-11-04 |
2020-09-30 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
|
CN101448523A
(zh)
|
2006-03-24 |
2009-06-03 |
诺华疫苗和诊断有限两合公司 |
无需冷藏储存流感疫苗
|
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
|
US20100010199A1
(en)
|
2006-09-11 |
2010-01-14 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
|
CN101553252A
(zh)
|
2006-12-06 |
2009-10-07 |
诺华有限公司 |
包含来自于四株流感病毒的抗原的疫苗
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
US20100047327A1
(en)
*
|
2007-01-31 |
2010-02-25 |
Tetsuji Kuwahara |
Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
|
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
WO2009081274A2
(en)
|
2007-12-21 |
2009-07-02 |
Novartis Ag |
Mutant forms of streptolysin o
|
|
EP2886551A3
(en)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningococcal fhbp polypeptides
|
|
EP2631245A1
(en)
|
2008-03-10 |
2013-08-28 |
Children's Hospital & Research Center at Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
|
SG186611A1
(en)
|
2008-12-09 |
2013-01-30 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
|
PL2396032T3
(pl)
|
2009-02-10 |
2017-05-31 |
Seqirus UK Limited |
Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
|
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
CA2758490C
(en)
|
2009-04-14 |
2023-05-02 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
|
CN102413838A
(zh)
|
2009-04-30 |
2012-04-11 |
科勒制药集团有限公司 |
肺炎球菌疫苗及其用途
|
|
SG176532A1
(en)
|
2009-06-15 |
2012-01-30 |
Univ Singapore |
Influenza vaccine, composition, and methods of use
|
|
ES2662716T3
(es)
|
2009-07-07 |
2018-04-09 |
Glaxosmithkline Biologicals Sa |
Inmunógenos conservados de Escherichia coli
|
|
EP2453918B1
(en)
|
2009-07-15 |
2015-12-16 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
SI2464658T1
(sl)
|
2009-07-16 |
2015-02-27 |
Novartis Ag |
Detoksificirani imunogeni escherichie coli
|
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
|
EP3017828A1
(en)
|
2009-08-27 |
2016-05-11 |
GlaxoSmithKline Biologicals SA |
Hybrid polypeptides including meningococcal fhbp sequences
|
|
AU2010290931B2
(en)
|
2009-09-03 |
2014-02-06 |
Pfizer Vaccines Llc |
PCSK9 vaccine
|
|
RU2603267C2
(ru)
|
2009-09-30 |
2016-11-27 |
Новартис Аг |
Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
CN102917730A
(zh)
|
2009-10-27 |
2013-02-06 |
诺华有限公司 |
修饰的脑膜炎球菌fHBP多肽
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
EP3257525A3
(en)
|
2009-12-22 |
2018-02-28 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
CN105315351A
(zh)
|
2010-03-30 |
2016-02-10 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白（fhbp）及其使用方法
|
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
|
CN102933267B
(zh)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
交互式混合异步计算机游戏基础结构
|
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
EP3153578A1
(en)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
|
LT2667892T
(lt)
|
2011-01-26 |
2019-05-10 |
Glaxosmithkline Biologicals Sa |
Rsv imunizacijos režimas
|
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
|
US20140248314A1
(en)
|
2011-05-13 |
2014-09-04 |
Novartis Ag |
Pre-fusion rsv f antigens
|
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
SG10201603896RA
(en)
|
2012-05-04 |
2016-07-28 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
KR20150021933A
(ko)
|
2012-05-22 |
2015-03-03 |
노파르티스 아게 |
수막염구균 혈청군 x 포합체
|
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
ES2672996T3
(es)
|
2012-10-02 |
2018-06-19 |
Glaxosmithkline Biologicals Sa |
Conjugados de sacáridos no lineales
|
|
KR20150073160A
(ko)
|
2012-10-03 |
2015-06-30 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
면역원성 조성물
|
|
HRP20180039T1
(hr)
|
2012-11-30 |
2018-04-06 |
Glaxosmithkline Biologicals S.A. |
Antigeni pseudomonasa i kombinacije antigena
|
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
|
ES2744454T3
(es)
|
2013-10-31 |
2020-02-25 |
Hisamitsu Pharmaceutical Co |
Composición de adyuvante
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
SG11201604728XA
(en)
|
2014-01-21 |
2016-08-30 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US10279019B2
(en)
|
2014-02-11 |
2019-05-07 |
Stc.Unm |
PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
|
|
KR102761870B1
(ko)
|
2014-07-23 |
2025-02-05 |
칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 |
인자 h 결합 단백질 변이체 및 이의 사용 방법
|
|
MX395525B
(es)
|
2015-01-15 |
2025-03-25 |
Pfizer |
Composiciones inmunogenicas para usar en vacunas neumococicas.
|
|
CA2986494A1
(en)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Il-23-p19 vaccines
|
|
CA2991544A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
|
BR112018000087A2
(pt)
|
2015-07-21 |
2018-09-04 |
Pfizer Inc. |
composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
|
|
EP4480544A3
(en)
|
2015-08-25 |
2025-03-26 |
Babita Agrawal |
Immunomodulatory compositions andmethods of use thereof
|
|
CN117229414A
(zh)
|
2015-10-08 |
2023-12-15 |
艾伯塔大学理事会 |
丙型肝炎病毒e1/e2异二聚体及其生产方法
|
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
SG11201805621SA
(en)
|
2016-01-19 |
2018-08-30 |
Pfizer |
Cancer vaccines
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
AU2018449744A1
(en)
|
2018-11-16 |
2021-05-27 |
Versitech Limited |
Live attenuated influenza B virus compositions methods of making and using thereof
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
CN114667343A
(zh)
|
2019-11-01 |
2022-06-24 |
辉瑞大药厂 |
大肠杆菌组合物及其方法
|
|
WO2021165847A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
|
CN115605498A
(zh)
|
2020-02-23 |
2023-01-13 |
辉瑞公司（Us） |
大肠杆菌组合物及其方法
|
|
WO2021169673A1
(en)
|
2020-02-26 |
2021-09-02 |
Versitech Limited |
Pd-1-based vaccines against coronavirus infection
|
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
MX2023005221A
(es)
|
2020-11-04 |
2023-05-16 |
Pfizer |
Composiciones inmunogenicas para uso en vacunas neumococicas.
|
|
WO2022101745A2
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TWI750929B
(zh)
*
|
2020-12-02 |
2021-12-21 |
林建宏 |
氣霧免疫用之溫敏型佐劑及其製作方法
|
|
EP4262876A4
(en)
*
|
2020-12-18 |
2024-05-29 |
Defence Therapeutics Inc. |
COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
US20240299510A1
(en)
|
2020-12-31 |
2024-09-12 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
|
EP4333868A1
(en)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
EP4346892A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US20250302943A1
(en)
|
2021-11-05 |
2025-10-02 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
|
AU2022391752A1
(en)
|
2021-11-18 |
2024-06-13 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
|
KR20240128715A
(ko)
|
2022-01-13 |
2024-08-26 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
|
CN119317445A
(zh)
|
2022-05-11 |
2025-01-14 |
辉瑞公司 |
用于生产含有防腐剂的疫苗制剂的方法
|
|
EP4558169A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
CN120265317A
(zh)
|
2022-11-22 |
2025-07-04 |
辉瑞公司 |
包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
|
|
IL321069A
(en)
|
2022-12-01 |
2025-07-01 |
Pfizer |
Pneumococcal conjugate vaccine preparations
|
|
WO2024130009A1
(en)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions and methods of use thereof for the treatment of virally driven cancers
|
|
EP4661911A1
(en)
|
2023-02-10 |
2025-12-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2024246082A1
(en)
|
2023-03-30 |
2025-10-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2024255922A1
(en)
|
2023-04-14 |
2025-10-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|